期刊
EPILEPSIA OPEN
卷 7, 期 -, 页码 S121-S132出版社
WILEY
DOI: 10.1002/epi4.12567
关键词
epilepsy; lipid nanoparticles; nanomedicine; nanotechnology; neurodegenerative diseases; polymeric nanoparticles
资金
- Spanish Ministry of Economy and Competitiveness [SAF2017-84283-R]
- Biomedical Research Networking Centre in Neurodegenerative Diseases [CB06/05/0024]
- Portuguese Science and Technology Foundation [UIDB/04469/2020]
Epilepsy, the second most common neurological disease globally, is characterized by abnormal electrical activity in the brain. Despite the availability of numerous antiseizure medications, there are patients who do not respond to treatment. Nanomedicine is considered a promising alternative to enhance drug effectiveness in managing epilepsy disorders.
Epilepsy is the second most prevalent neurological disease worldwide. It is mainly characterized by an electrical abnormal activity in different brain regions. The massive entrance of Ca2+ into neurons is the main neurotoxic process that lead to cell death and finally to neurodegeneration. Although there are a huge number of antiseizure medications, there are many patients who do not respond to the treatments and present refractory epilepsy. In this context, nanomedicine constitutes a promising alternative to enhance the central nervous system bioavailability of antiseizure medications. The encapsulation of different chemical compounds at once in a variety of controlled drug delivery systems gives rise to an enhanced drug effectiveness mainly due to their targeting and penetration into the deepest brain region and the protection of the drug chemical structure. Thus, in this review we will explore the recent advances in the development of drugs associated with polymeric and lipid-based nanocarriers as novel tools for the management of epilepsy disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据